Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 15:17:623-639.
doi: 10.2147/IDR.S419243. eCollection 2024.

Microbiota-Based Live Biotherapeutic Products for Clostridioides Difficile Infection- The Devil is in the Details

Lea Monday  1 , Glenn Tillotson  2 , Teena Chopra  1
Affiliations
Review

Microbiota-Based Live Biotherapeutic Products for Clostridioides Difficile Infection- The Devil is in the Details

Lea Monday et al. Infect Drug Resist. .

Abstract

Clostridioides difficile infection (CDI) remains a significant contributor to healthcare costs and morbidity due to high rates of recurrence. Currently, available antibiotic treatment strategies further disrupt the fecal microbiome and do not address the alterations in commensal flora (dysbiosis) that set the stage for CDI. Advances in microbiome-based research have resulted in the development of new agents, classified as live biotherapeutic products (LBPs), for preventing recurrent CDI (rCDI) by restoring eubiosis. Prior to the LBPs, fecal microbiota transplantation (FMT) was available for this purpose; however, lack of large-scale availability and safety concerns have remained barriers to its widespread use. The LBPs are an exciting development, but questions remain. Some are derived directly from human stool while other developmental products contain a defined microbial consortium manufactured ex vivo, and they may be composed of either living bacteria or their spores, making it difficult to compare members of this heterogenous drug class to one another. None have been studied head-to head or against FMT in preventing rCDI. As a class, they have considerable variability in their biologic composition, biopharmaceutic science, route of administration, stages of development, and clinical trial data. This review will start by explaining the role of dysbiosis in CDI, then give the details of the biopharmaceutical components for the LBPs which are approved or in development including how they differ from FMT and from one another. We then discuss the clinical trials of the LBPs currently approved for rCDI and end with the future clinical directions of LBPs beyond C. difficile.

Keywords: Clostridioides difficile infection; indirect treatment comparison; microbiome; microbiome therapeutic.

PubMed Disclaimer

Conflict of interest statement

Dr Glenn Tillotson is a consultant for Ferring Pharmaceuticals, Spero Therapeutics, and Taro Pharmaceuticals, outside the submitted work. The author reports no other conflicts of interest in this work.

References

    1. Martin TC, Visconti A, Spector TD, et al. Conducting metagenomic studies in microbiology and clinical research. Appl Microbiol Biotechnol. 2018;102(20):8629–8646. doi:10.1007/s00253-018-9209-9 - DOI - PMC - PubMed
    1. Integrative, HMP. The integrative human microbiome project. Nature. 2019;569(7758):641–648. doi:10.1038/s41586-019-1238-8 - DOI - PMC - PubMed
    1. Oliveira RA, Pamer EG. Assembling symbiotic bacterial species into live therapeutic consortia that reconstitute microbiome functions. Cell Host Microbe. 2023;31(4):472–484. doi:10.1016/j.chom.2023.03.002 - DOI - PubMed
    1. Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs. 2010;70(8):965–981. doi:10.2165/10898540-000000000-00000 - DOI - PubMed
    1. Seres therapeutics announces strategic collaboration with nestlé health science for microbiome-based clostridium difficile and inflammatory bowel disease therapies in markets outside of north America. 2016.